Taka forma ma chroni czsteczki przed rozkadem w przewodzie pokarmowym i w efekcie moe zwikszy ich przyswajanie
In the REDEFINE 1 phase 3 trial (NCT05567796), which enrolled adults with overweight or obesity (BMI 27 kg/m) and at least 1 weight-related comorbidity but without type 2 diabetes, participants receiving CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) achieved a mean body weight reduction of 22.7% from baseline after 68 weeks among adherent participants, compared with approximately 3% in the placebo group.5 These results establish CagriSema as one of the most potent antiobesity therapies investigated to date
Cardiovascular diabetology
Because this drug has received approval for an accepted medical indication, Part D plan sponsors can add it to their formularies now and cover the medication
a) Distribution of pre-treatment weight
Other clinical data showed microbiota shifts (fewer beneficial, more harmful bacteria) with constipation and delayed gastric emptying, underscoring the diagnostic significance of microbiota composition changes [34]
